Sigyn Therapeutics Inc Financials
This page shows Sigyn Therapeutics Inc (SIGY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Sigyn’s development-stage model runs on external financing, with cash burn easing but liquid resources staying far below near-term obligations.
In FY2024, operating cash outflow of-$872K was almost exactly offset by financing inflow of$873K . FY2023 showed the same near one-for-one pattern, so new capital was replacing consumed cash almost dollar for dollar rather than building reserves; cash still ended FY2024 at only$12K .
Research spending stayed close to steady, moving from
The balance sheet became more near-term liability heavy: current liabilities reached
Financial Health Signals
Sigyn Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Sigyn Therapeutics Inc earned -$2.51 per diluted share (EPS) in fiscal year 2024. This represents an increase of 33.4% from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Sigyn Therapeutics Inc held $12K in cash against $2.0M in long-term debt as of fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
None of these metrics is reported for fiscal year 2024.
Capital Allocation
Sigyn Therapeutics Inc invested $773K in research and development in fiscal year 2024. This represents a decrease of 3.1% from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
SIGY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $143K+405.6% | $28K-26.2% | $38K | $29K-32.3% | $43K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $36K+267.2% | $10K-54.7% | $21K | $10K-60.7% | $25K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | $108K+477.7% | $19K+9.6% | $17K | $19K+7.7% | $18K |
| R&D Expenses | N/A | $773K-3.1% | $798K+21.4% | $658K-10.4% | $734K+75.0% | $419K | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | $1.5M+16.9% | $1.3M+156.7% | $496K-19.1% | $614K-28.8% | $862K-18.0% | $1.1M | $834K+108.4% | $400K |
| Operating Income | N/A | N/A | N/A | N/A | -$2.0M-119.1% | -$916K-76.9% | -$518K+48.4% | -$1.0M+50.5% | -$2.0M | -$2.3M-481.4% | -$388K |
| Interest Expense | N/A | N/A | N/A | N/A | $31K-91.0% | $343K+521.7% | $55K-84.4% | $353K-55.4% | $791K | -$441K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $8000.0% | $800 | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | -$3.0M-138.5% | -$1.3M+59.0% | -$3.1M-17.3% | -$2.6M+38.4% | -$4.3M | -$2.7M-595.2% | -$388K |
| EPS (Diluted) | — | -$2.51+33.4% | -$3.77 | -$3.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
No annual filing on record for: FY2016.
SIGY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $214K-33.6% | $322K-3.3% | $333K-53.1% | $710K+2.3% | $694K | $0-100.0% | $862K-58.4% | $2.1M | $1.4M+153.8% | $562K |
| Current Assets | $21K-82.0% | $118K+67.9% | $70K-82.1% | $393K-41.4% | $670K+13.9% | $589K-19.7% | $733K-3.6% | $761K | $1.2M+140.2% | $484K |
| Cash & Equivalents | $12K+3.9% | $12K+39.9% | $8K-97.5% | $341K+304.0% | $84K+16780.4% | $500-93.3% | $7K-21.8% | $10K | $639K+672346.3% | $95 |
| Inventory | N/A | $50K0.0% | $50K0.0% | $50K-91.5% | $586K-0.4% | $588K-18.7% | $724K-0.4% | $726K | $510K+20.7% | $423K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $10K | N/A | $9K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $482K | N/A | N/A |
| Total Liabilities | $4.7M+25.1% | $3.7M+67.0% | $2.2M+129.4% | $975K+63.9% | $595K+65274.0% | $910-100.0% | $4.6M+9.9% | $4.2M | $1.5M+226.0% | $463K |
| Current Liabilities | $4.6M+27.9% | $3.6M+76.1% | $2.0M+179.0% | $734K+23.4% | $595K+65274.0% | $910-100.0% | $4.6M+9.9% | $4.2M | $1.5M+223.3% | $463K |
| Long-Term Debt | $2.0M-19.4% | $2.5M+10.0% | $2.3M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$4.5M-30.6% | -$3.4M-79.3% | -$1.9M-619.3% | -$265K-366.8% | $99K+10998.8% | -$910+100.0% | -$3.7M-77.4% | -$2.1M | -$82K-182.5% | $99K |
| Retained Earnings | -$14.7M-29.5% | -$11.3M-57.6% | -$7.2M-68.7% | -$4.3M-238.2% | -$1.3M-81263.9% | -$2K+100.0% | -$13.0M-25.2% | -$10.4M | -$3.3M-426.1% | -$632K |
No annual filing on record for: FY2016.
SIGY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$936K | -$872K+36.9% | -$1.4M | N/A | -$1.8M-113.8% | -$830K-477.5% | -$144K+49.8% | -$286K+28.5% | -$400K | -$84K-88.6% | -$44K |
| Capital Expenditures | N/A | N/A | N/A | $860-97.1% | $29K | N/A | N/A | $3K+213.8% | $940 | $2K-29.3% | $3K |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$1.8M | N/A | N/A | -$289K+27.9% | -$401K | -$86K-80.1% | -$48K |
| Investing Cash Flow | N/A | N/A | N/A | -$860+97.1% | -$29K-171.0% | -$11K-110.8% | $100K+1283.2% | -$8K+89.3% | -$79K | N/A | N/A |
| Financing Cash Flow | $857K | $873K-37.0% | $1.4M-7.5% | $1.5M-27.3% | $2.1M+122.7% | $925K+2421.4% | $37K-87.5% | $292K-13.7% | $339K | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
No annual filing on record for: FY2016.
SIGY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | 75.1%+9.4pp | 65.7%+21.5pp | 44.2% | 66.0%+24.5pp | 41.5% |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | -361.4% | -3544.2% | -5277.4% | -7714.4% | -898.0% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -2145.3% | -9243.2% | -11061.2% | -9224.9% | -898.0% |
| Return on Equity | N/A | N/A | N/A | N/A | -1270.0% | N/A | N/A | N/A | N/A | -389.8% |
| Return on Assets | N/A | N/A | N/A | -423.0%-241.5pp | -181.5% | N/A | -304.0%-98.7pp | -205.3% | -188.8%-119.9pp | -68.9% |
| Current Ratio | 0.000.0x | 0.030.0x | 0.03-0.5x | 0.54-0.6x | 1.13-645.7x | 646.82+646.7x | 0.160.0x | 0.18 | 0.78-0.3x | 1.05 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | 6.00 | N/A | N/A | N/A | N/A | 4.65 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1019.7% | -1043.2% | -295.4% | -111.0% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
No annual filing on record for: FY2016.
Note: Shareholder equity is negative (-$4.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Sigyn Therapeutics Inc Ranks
Frequently Asked Questions
How much debt does Sigyn Therapeutics Inc have?
As of fiscal year 2024, Sigyn Therapeutics Inc (SIGY) had $12K in cash and equivalents against $2.0M in long-term debt.
What is Sigyn Therapeutics Inc's operating cash flow?
Sigyn Therapeutics Inc (SIGY) recorded an outflow of $872K in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Sigyn Therapeutics Inc's total assets?
Sigyn Therapeutics Inc (SIGY) had $214K in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Sigyn Therapeutics Inc spend on research and development?
Sigyn Therapeutics Inc (SIGY) invested $773K in research and development during fiscal year 2024.
What is Sigyn Therapeutics Inc's current ratio?
Sigyn Therapeutics Inc (SIGY) had a current ratio of 0.00 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
How does Sigyn Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, Sigyn Therapeutics Inc (SIGY) held $12K in cash, cash equivalents and investments, and reported an operating cash outflow of $872K over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Sigyn Therapeutics Inc's debt-to-equity ratio negative or not reported?
Sigyn Therapeutics Inc (SIGY) has negative shareholder equity of -$4.5M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.